Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 8/2016

17.12.2015 | Retinal Disorders

Cooperation of German ophthalmologists in routine care of patients with neovascular age-related macular degeneration: results of the non-interventional BRIDGE study

verfasst von: Joachim Wachtlin, Andreas Ringwald, Tobias Maulhardt, Karin Pohl, Annette Wiedon, for the BRIDGE investigators

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In the non-interventional ophthalmological study ‘BRIDGE’ the routine care of patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab was observed in Germany. A patient regularly sees the general ophthalmologist (GO) for monitoring and, if needed, the injecting ophthalmologist (IO) for intravitreal injections (IVI). Thus, patients are routinely treated by two ophthalmologists in parallel and patient care depends on their collaboration. This cooperation was evaluated based on network questionnaires.

Methods

‘BRIDGE’ was a multicenter, national, open-label, prospective, observational study, conducted between July 2010 and December 2012. The network questionnaire for GOs consisted of 51 questions, while the similar questionnaire for IOs consisted of 43 questions, addressing the type and details of the individual collaboration. The statistical analysis was purely descriptive.

Results

The network questionnaire for GOs was completed by 152 GOs, regularly cooperating with 2.5 ± 1.1 IOs, while the questionnaire for IOs was completed by 43 IOs, regularly cooperating with 23.2 ± 23.6 GOs. Generally, both GOs and IOs stated that they regularly exchange information regarding the patients’ situation. Diagnostic standards were only established for 15 % of the GOs’ collaborations and for 35 % of the IOs’ collaborations. After initial treatment, both GOs and IOs agreed on the medical significance of regular monitoring visits performed by the GOs. Agreements on re-treatment criteria were only established in the case of 16 % of the GOs and 28 % of the IOs. Overall, both GOs and IOs were satisfied with the current situation, with regard to the medical treatment situation for patients and to the cooperation within the networks.

Conclusions

The network questionnaires revealed well-established cooperation between IOs and GOs in Germany with an accepted division of responsibilities for the routine care of patients with nAMD. However, the cooperation between two ophthalmologists treating one patient harbors risks. Agreements on diagnostic and re-treatment criteria would help to improve network performance and outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Finger RP, Fimmers R, Holz FG, Scholl HP (2011) Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 52:4381–4389CrossRefPubMed Finger RP, Fimmers R, Holz FG, Scholl HP (2011) Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 52:4381–4389CrossRefPubMed
2.
Zurück zum Zitat Wolfram C, Pfeiffer N (2012) Weissbuch zur Situation der opththalmologischen Versorgung in Deutschland. DOG Deutsche Ophthalmogische Gesellschaft, Munich Wolfram C, Pfeiffer N (2012) Weissbuch zur Situation der opththalmologischen Versorgung in Deutschland. DOG Deutsche Ophthalmogische Gesellschaft, Munich
4.
Zurück zum Zitat The Retinological Society (2009) The German Ophthalmology Society and the Professional Union of Ophthalmologists in Germany, New aspects in the management of exudative age-related macular degeneration—current position. Klin Monatsbl Augenheilkd 226:388–395CrossRef The Retinological Society (2009) The German Ophthalmology Society and the Professional Union of Ophthalmologists in Germany, New aspects in the management of exudative age-related macular degeneration—current position. Klin Monatsbl Augenheilkd 226:388–395CrossRef
5.
Zurück zum Zitat The Retinological Society (2011) The German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany, New options in the therapy for neovascular age-related macular degeneration: critieria for repeat treatment in anti-VEGF therapy- current supplementary statement. Klin Monatsbl Augenheilkd 228:138–143CrossRef The Retinological Society (2011) The German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany, New options in the therapy for neovascular age-related macular degeneration: critieria for repeat treatment in anti-VEGF therapy- current supplementary statement. Klin Monatsbl Augenheilkd 228:138–143CrossRef
6.
Zurück zum Zitat Mitchell P, Annemans L, White R, Gallagher M, Thomas S (2011) Cost effectiveness of treatments for wet age-related macular degeneration. PharmacoEconomics 29:107–131CrossRefPubMed Mitchell P, Annemans L, White R, Gallagher M, Thomas S (2011) Cost effectiveness of treatments for wet age-related macular degeneration. PharmacoEconomics 29:107–131CrossRefPubMed
7.
Zurück zum Zitat Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453–458CrossRefPubMed Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453–458CrossRefPubMed
8.
Zurück zum Zitat Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S, Schneider V, LUMIERE Study Group (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33(3):474–481CrossRefPubMed Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S, Schneider V, LUMIERE Study Group (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33(3):474–481CrossRefPubMed
9.
Zurück zum Zitat Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99(2):220–226CrossRefPubMed Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99(2):220–226CrossRefPubMed
10.
Zurück zum Zitat Ziemssen F, Eter N, Fauser S, Bopp S, Radermacher M, Hasanbasic Z, Holz FG, AURA Study Group (2015) Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany. Ophthalmologe 112(3):246–254CrossRefPubMed Ziemssen F, Eter N, Fauser S, Bopp S, Radermacher M, Hasanbasic Z, Holz FG, AURA Study Group (2015) Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany. Ophthalmologe 112(3):246–254CrossRefPubMed
11.
Zurück zum Zitat Milojcic C, Clemens CR, Fimmers R, Quade G, Alten F, Sarbach P, Eter N (2014) BOON (Bonn ophthalmology online network). Concept of an integrative databank for monitoring patients under intravitreal therapy. Ophthalmologe 111(1):37–43CrossRefPubMed Milojcic C, Clemens CR, Fimmers R, Quade G, Alten F, Sarbach P, Eter N (2014) BOON (Bonn ophthalmology online network). Concept of an integrative databank for monitoring patients under intravitreal therapy. Ophthalmologe 111(1):37–43CrossRefPubMed
12.
Zurück zum Zitat Heimann H, Yang Y, Wachtlin J, Pauleikhoff D (2011) Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain. Ophthalmologe 108(6):575–584CrossRefPubMed Heimann H, Yang Y, Wachtlin J, Pauleikhoff D (2011) Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain. Ophthalmologe 108(6):575–584CrossRefPubMed
13.
Zurück zum Zitat Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121(5):1092–1101CrossRef Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121(5):1092–1101CrossRef
Metadaten
Titel
Cooperation of German ophthalmologists in routine care of patients with neovascular age-related macular degeneration: results of the non-interventional BRIDGE study
verfasst von
Joachim Wachtlin
Andreas Ringwald
Tobias Maulhardt
Karin Pohl
Annette Wiedon
for the BRIDGE investigators
Publikationsdatum
17.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 8/2016
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-015-3242-5

Weitere Artikel der Ausgabe 8/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 8/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.